Search research articles
Contact Us
Filters
Showing results (51-60 of 62) with videos related to
Page
of 7
Sort By:
Clinical and Translational Science
|
April 4, 2017
Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide
S Bins, L van Doorn, M A Phelps, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 1998
Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies
M A Villalona-Calero, S D Baker, L Hammond, et al.
Clinical Pharmacology and Therapeutics
|
September 20, 2012
OATP1B1 polymorphism as a determinant of erythromycin disposition
C S Lancaster, G H Bruun, C J Peer, et al.
Clinical Pharmacology and Therapeutics
|
December 15, 2015
Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia
C D Drenberg, S W Paugh, S B Pounds, et al.
Leukemia
|
June 11, 2010
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias
K W Pratz, E Cho, M J Levis, et al.
Clinical Pharmacology and Therapeutics
|
May 30, 2008
Pharmacogenetic pathway analysis of docetaxel elimination
S D Baker, J Verweij, G A Cusatis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 1999
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies
C D Britten, E K Rowinsky, S D Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 1999
A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors
S G Diab, S D Baker, A Joshi, et al.
Clinical and Translational Science
|
July 10, 2017
Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity
S Hu, A F Leblanc, A A Gibson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 14, 1998
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks
S G Eckhardt, S D Baker, J R Eckardt, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 62) with videos related to
Sort By:
Page
of 7
Clinical and Translational Science
|
April 4, 2017
Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide
S Bins, L van Doorn, M A Phelps, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 1998
Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies
M A Villalona-Calero, S D Baker, L Hammond, et al.
Clinical Pharmacology and Therapeutics
|
September 20, 2012
OATP1B1 polymorphism as a determinant of erythromycin disposition
C S Lancaster, G H Bruun, C J Peer, et al.
Clinical Pharmacology and Therapeutics
|
December 15, 2015
Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia
C D Drenberg, S W Paugh, S B Pounds, et al.
Leukemia
|
June 11, 2010
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias
K W Pratz, E Cho, M J Levis, et al.
Clinical Pharmacology and Therapeutics
|
May 30, 2008
Pharmacogenetic pathway analysis of docetaxel elimination
S D Baker, J Verweij, G A Cusatis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 1999
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies
C D Britten, E K Rowinsky, S D Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 1999
A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors
S G Diab, S D Baker, A Joshi, et al.
Clinical and Translational Science
|
July 10, 2017
Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity
S Hu, A F Leblanc, A A Gibson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 14, 1998
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks
S G Eckhardt, S D Baker, J R Eckardt, et al.
Page
of 7